Nicholas J Sarlis
SELLAS Life Sciences Group, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nicholas J Sarlis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:24 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03761914 · Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersSellas Life Sciences Group · completed · Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:24 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.Haematologica · 2015224 citationsRCR 7.1
- Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin.J Clin Endocrinol Metab · 2000153 citationsRCR 4.6
- Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor.J Clin Endocrinol Metab · 200181 citationsRCR 1.7
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.Ann Oncol · 201266 citationsRCR 2.4
- 50 citationsRCR 1.3
- Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.Int J Radiat Oncol Biol Phys · 201141 citationsRCR 1.3
- 18 citationsRCR 0.7